

Resource Summary Report

Generated by [kravitz2](#) on Jul 30, 2026

CD8 antibody

RRID:AB_2882205

Type: Antibody

Proper Citation

Proteintech Cat# 66868-1-Ig, RRID:AB_2882205

Antibody Information

URL: http://antibodyregistry.org/AB_2882205

Proper Citation: Proteintech Cat# 66868-1-Ig, RRID:AB_2882205

Target Antigen: CD8

Host Organism: mouse

Clonality: monoclonal

Comments: Originating manufacturer of this product.
Applications: WB, IHC, IF, ELISA

Antibody Name: CD8 antibody

Description: This monoclonal targets CD8

Target Organism: mouse, human

Clone ID: 1G2B10

Antibody ID: AB_2882205

Vendor: Proteintech

Catalog Number: 66868-1-Ig

Record Creation Time: 20250820T000046+0000

Record Last Update: 20250820T070629+0000

Ratings and Alerts

No rating or validation information has been found for CD8 antibody.

No alerts have been found for CD8 antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 16 mentions in open access literature.

Listed below are recent publications. The full list is available at [kravitz2](#) .

Fan Y, et al. (2025) Itaconate transporter SLC13A3 confers immunotherapy resistance via alkylolation-mediated stabilization of PD-L1. *Cell metabolism*, 37(2), 514.

Wang L, et al. (2025) ANLN promotes head and neck squamous cell carcinoma progression by upregulating PD-L1 via the ERK-MAPK pathway. *iScience*, 28(2), 111633.

Zhao J, et al. (2025) Proteomics and single cell profiling identify keratin driven preexisting immunity influences lung squamous carcinoma neoadjuvant therapy. *Cancer letters*, 633, 218000.

Tian N, et al. (2025) Mature tertiary lymphoid structures support B cell-mediated antitumour immunity and are disrupted by neoadjuvant therapy in rectal cancer: a multicentre, retrospective study. *EBioMedicine*, 122, 106030.

Luo B, et al. (2025) Resveratrol amplifies the anti-tumor effect of γ -PD-1 by altering the intestinal microbiome and PGD2 content. *Gut microbes*, 17(1), 2447821.

Zhang D, et al. (2025) Glutamine binds HSC70 to transduce signals inhibiting IFN- γ -mediated immunogenic cell death. *Developmental cell*, 60(14), 1958.

Ma D, et al. (2025) Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. *Cancer cell*, 43(6), 1061.

Wang JM, et al. (2025) KIF26B promotes bladder cancer progression via activating Wnt/ β -catenin signaling in a TRAF2-dependent pathway. *Cell reports*, 44(5), 115595.

Zhang S, et al. (2025) p57 increases immunotherapy efficacy by promoting cGAS-STING-mediated innate sensing in hepatocellular carcinoma. *Cell reports*, 45(1), 116769.

Ma H, et al. (2024) Pirin Inhibits FAS-Mediated Apoptosis to Support Colorectal Cancer Survival. *Advanced science (Weinheim, Baden-Wurttemberg, Germany)*, 11(10), e2301476.

Meng H, et al. (2024) ZG16 enhances the maturation of dendritic cells via induction of CD40 and contributes to the antitumor immunity in pancreatic cancer. *Oncogene*, 43(43), 3184.

Peng L, et al. (2024) Hippo-signaling-controlled MHC class I antigen processing and presentation pathway potentiates antitumor immunity. *Cell reports*, 43(4), 114003.

Liu B, et al. (2024) Distinctive multicellular immunosuppressive hubs confer different intervention strategies for left- and right-sided colon cancers. *Cell reports. Medicine*, 5(6), 101589.

Jiang Y, et al. (2024) Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. *Cell metabolism*, 36(8), 1806.

Wu Q, et al. (2022) Remodeling Chondroitin-6-Sulfate-Mediated Immune Exclusion Enhances Anti-PD-1 Response in Colorectal Cancer with Microsatellite Stability. *Cancer immunology research*, 10(2), 182.

Wei B, et al. (2021) SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer. *Cancer research*, 81(12), 3215.